Targeting a parasite that causes blindness using a new approach
Src Inhibition Induces Selective Autophagic Killing of T. gondii Independently of EGF Receptor
This study is looking at how a parasite that can cause eye problems survives in our cells and how we can help the body get rid of it better, especially for people who haven't had success with current treatments.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11066496 on NIH RePORTER |
What this research studies
This research investigates how the parasite Toxoplasma gondii, which can lead to blindness, survives in human cells and how it can be targeted for destruction. The study focuses on a specific signaling molecule called Src that the parasite uses to evade the body's natural defense mechanisms. By inhibiting Src, the researchers aim to enhance the process of autophagy, which is the body's way of cleaning out damaged cells and pathogens. This approach could lead to more effective treatments for ocular toxoplasmosis, especially for patients who do not respond well to current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with ocular toxoplasmosis who are at risk of vision loss.
Not a fit: Patients with ocular toxoplasmosis who have already lost vision or those with other unrelated eye conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients suffering from ocular toxoplasmosis, potentially reducing the risk of blindness.
How similar studies have performed: Previous research has shown that targeting similar pathways can lead to partial protection against ocular toxoplasmosis, suggesting potential for success with this novel approach.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Hubal, Alyssa — Case Western Reserve University
- Study coordinator: Hubal, Alyssa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.